KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-cash Items (2010 - 2018)

Alnylam Pharmaceuticals posted quarterly Non-cash Items of $5.7 million for Q4 2018, down 95.37% year-on-year from $123.8 million in Q4 2017, and down 95.37% on a QoQ basis from $123.8 million in Q4 2017.

Alnylam Pharmaceuticals (ALNY) has 9 years of Non-cash Items data on file, last reported at $5.7 million in Q4 2018.

  • For the quarter ending Q4 2018, Non-cash Items fell 95.37% year-over-year to $5.7 million; the trailing twelve-month figure through Dec 2018 stood at $5.7 million (down 95.37% YoY), and the FY2018 full-year result was $5.7 million, down 95.37% from the prior year.
  • Non-cash Items for Q4 2018 stood at $5.7 million, down from $123.8 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $478.5 million in Q4 2014 and bottomed at $5.7 million in Q4 2018.
  • The 5-year median for Non-cash Items is $123.8 million (2017), against an average of $205.1 million.
  • The widest annual swing landed in 2014, when Non-cash Items jumped 8887.01%; it then sank 95.37% in 2018.
  • A 5-year view of Non-cash Items shows it stood at $478.5 million in 2014, then fell by 26.3% to $352.6 million in 2015, then slumped by 81.64% to $64.8 million in 2016, then surged by 91.19% to $123.8 million in 2017, then tumbled by 95.37% to $5.7 million in 2018.
  • The last three Non-cash Items figures came in at $5.7 million (Q4 2018), $123.8 million (Q4 2017), and $64.8 million (Q4 2016), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2018 5.73 Mn
Dec 31, 2018 5.73 Mn
Dec 31, 2017 123.80 Mn
Dec 31, 2017 123.80 Mn
Dec 31, 2016 64.75 Mn
Dec 31, 2016 64.75 Mn
Dec 31, 2015 352.65 Mn
Dec 31, 2015 352.65 Mn
Dec 31, 2014 478.51 Mn
Dec 31, 2014 478.51 Mn
Dec 31, 2013 5.32 Mn
Dec 31, 2013 5.32 Mn
Dec 31, 2012 14.70 Mn
Dec 31, 2012 14.70 Mn
Dec 31, 2011 6.03 Mn
Dec 31, 2011 6.03 Mn
Dec 31, 2010 4.98 Mn
Dec 31, 2010 4.98 Mn